Onartuzumab

N/A

Report date: 2023/06/29 20:00:29

Base Information

Drug NameOnartuzumab
Drug Alias Nameanti-c-Met monoclonal antibody - Genentech奥那妥珠单抗hOA-5D5.v2MetMAbOA-5D5 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsDiagnostic imaging enhancers
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[39] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdThe University Of Texas MD Anderson Cancer CenterGenentech Inc +[4] 
Active IndicationsN/A
Inactive IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[10] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG